NASA Logo

NTRS

NTRS - NASA Technical Reports Server

Back to Results
Experimental motion sickness - Efficacy of transdermal scopolamine plus ephedrineA double-blind, placebo-controlled study compared the efficacy of transdermal therapeutic system-scopolamine administered alone and combined with ephedrine sulfate given orally in doses of 12.5, 25, and 50 mg. Eight normal male students were exposed to stressful accelerations in a slow-rotation room after receiving 10 apparently identical treatments comprising the four drugs and six placebos. Efficacy of the drug was defined in terms of the placebo range and categorized as beneficial, inconsequential, or detrimental. None of the effects was detrimental. Overall beneficial effects were 60% for transdermal therapeutic system-scopolamine (plus placebo) and 57% for the three transdermal therapeutic system-scopolamine plus ephedrine combinations.
Document ID
19810052882
Acquisition Source
Legacy CDMS
Document Type
Reprint (Version printed in journal)
Authors
Graybiel, A.
(U.S. Medical Aerospace Medical Center Aerospace Medical Research Laboratory, Pensacola, Fla., United States)
Cramer, D. B.
(NASA Headquarters Washington, DC United States)
Wood, C. D.
(U.S. Naval Aerospace Medical Center Aerospace Medical Research Laboratory, Pensacola, Fla.; Louisiana State University, Shreveport, La., United States)
Date Acquired
August 11, 2013
Publication Date
June 1, 1981
Subject Category
Aerospace Medicine
Accession Number
81A37286
Funding Number(s)
CONTRACT_GRANT: NASA ORDER T-3384-G
Distribution Limits
Public
Copyright
Other

Available Downloads

There are no available downloads for this record.
No Preview Available